Arcturus Therapeutics (ARCT) Prices 1.365M Share Common Offering at $110/Sh

After-Hours Stock Movers 12/07: (SFIX) (HOLI) (SMAR) Higher; (MRNS) (IBIO) (ARCT) Lower (more...)

After-Hours Stock Movers

Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that Dan Jedda has joined the company, reporting to Katrina Lake. Jedda will be appointed CFO effective December 9, 2020. Dan Jedda joins the company from Amazon where he was Vice President and CFO for Digital Video (including Amazon Studios), Digital Music, and the Advertising and Corporate Development organizations.

Hollysys Automation (NASDAQ:... More

Arcturus Therapeutics (ARCT) Announces Proposed Public Offering of Common Stock

Arcturus Therapeutics Holdings Inc. (the Company, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its... More

Arcturus Therapeutics (ARCT) PT Raised to $138 at B.Riley/FBR, Following Clinical Update

B.Riley/FBR analyst Chad L. Mabry raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $138.00 (from $111.00) while maintaining a Buy rating.

Arcturus Therapeutics (ARCT) PT Raised to $172 at Brookline Capital Markets, Following Clinical Update

Brookline Capital Markets analyst Kumaraguru Raja raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $172.00 (from $81.00) while maintaining a Buy rating.

UPDATE: Correction: Arcturus Therapeutics (ARCT) PT Raised to $111 at B.Riley/FBR, Not Novavax (NVAX)

(Updated - December 4, 2020 11:34 AM EST)

(Update to correct company name, previously reported Novavax, Inc. (NVAX).)

B.Riley/FBR analyst Chad L. Mabry raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $111.00 (from $64.00) while maintaining a Buy rating.